A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
A Phase III study comparing Mesutoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed acute myeloid leukemia (AML) patients
Trial Details
- NCT ID
- NCT07925190
- Phase
- PHASE3
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Mesutoclax (ICP-248)
- Azacitidine (AZA)
- Venetoclax
- Locations (sample)
- Hangzhou, Zhejiang, China|30.29365,120.16142
Key Eligibility Criteria
- Study participants with newly diagnosed AML (excluding acute promyelocytic leukemia \[APL\]) confirmed per the 2022 World Health Organization (WHO)…
- Age ≥65 years; or age ≥18 years and \<65 years and ineligible for intensive chemotherapy.
- The participant is expected to have a survival time of at least 12 weeks.
- For participants aged ≥65 years: ECOG Performance Status (PS) 0-2; for participants aged ≥18 years and \<65 years: ECOG PS 0-3.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →